Velasof Tablet

Velasof Tablet is a highly effective direct-acting antiviral (DAA) medication used for the treatment of chronic Hepatitis C Virus (HCV) infection. It is a fixed-dose combination containing Sofosbuvir 400 mg and Velpatasvir 100 mg, two advanced antiviral agents that work together to eliminate the Hepatitis C virus by targeting multiple stages of its replication cycle. This once-daily oral therapy has become one of the most preferred treatment options worldwide because of its exceptional cure rates, broad genotype coverage, convenient dosing regimen, and excellent safety profile. Velasof offers patients an opportunity to achieve complete viral clearance while significantly reducing the risk of long-term liver complications.

Velasof combines the proven antiviral action of Sofosbuvir, an NS5B RNA polymerase inhibitor, with Velpatasvir, an NS5A inhibitor. Sofosbuvir works by preventing the Hepatitis C virus from replicating its RNA, effectively stopping the production of new viral particles. Velpatasvir blocks the NS5A protein, which plays a critical role in viral replication and assembly. The combination of these two medicines attacks the virus through different mechanisms, resulting in a powerful antiviral effect that minimizes viral resistance and maximizes treatment success. This dual-action therapy has revolutionized the treatment of Hepatitis C by providing a highly effective, interferon-free solution.

One of the key advantages of Velasof Tablet is its pan-genotypic activity, making it effective against all major Hepatitis C genotypes (Genotypes 1, 2, 3, 4, 5, and 6). This broad-spectrum coverage simplifies treatment decisions and makes Velasof suitable for a wide range of patients. The medication is commonly prescribed for individuals with chronic Hepatitis C, including patients with compensated cirrhosis and many treatment-naïve or previously treated patients. Depending on the patient's clinical condition, viral load, and liver health, the standard treatment duration is generally 12 weeks, although certain patients with advanced liver disease may require extended therapy as advised by their healthcare provider.

Clinical studies have demonstrated outstanding sustained virologic response (SVR) rates of more than 95%, meaning that the virus becomes undetectable in the bloodstream after completing the prescribed course of treatment. Achieving SVR is considered a functional cure for Hepatitis C and greatly reduces the risk of liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Early diagnosis and timely treatment with Velasof can significantly improve long-term liver health and enhance overall quality of life.

Velasof Tablet is administered orally as one tablet once daily, with or without food, preferably at the same time each day to maintain consistent drug levels in the body. Patients should strictly follow their physician's instructions and complete the entire treatment course without interruption. Missing doses or discontinuing therapy prematurely may reduce treatment effectiveness and increase the risk of viral relapse.

Compared with older interferon-based therapies, Velasof is generally very well tolerated and is associated with fewer side effects. The most commonly reported side effects include headache, fatigue, nausea, mild diarrhea, dizziness, and weakness. These symptoms are usually mild and temporary, allowing most patients to continue their normal daily activities throughout the treatment period. Serious adverse effects are uncommon when the medication is used under appropriate medical supervision. Regular follow-up appointments and laboratory monitoring may be recommended to assess treatment progress and ensure optimal therapeutic outcomes.

Before beginning treatment, patients should inform their healthcare provider about any history of liver disease, kidney impairment, hepatitis B infection, HIV infection, pregnancy, breastfeeding, or any medications, vitamins, or herbal supplements they are taking. Certain drugs may interact with Sofosbuvir or Velpatasvir, requiring dosage adjustments or additional monitoring. Alcohol consumption should be avoided during treatment, as it can further damage the liver and reduce the overall benefits of antiviral therapy.

Velasof Tablets should be stored in their original packaging in a cool, dry place away from direct sunlight, excessive heat, and moisture. The medicine should be kept out of the reach of children and should not be used after the printed expiration date. Proper storage helps preserve the stability, potency, and effectiveness of the medication throughout its shelf life.

At Ayurmed Medicose, we are dedicated to supplying authentic, high-quality antiviral medicines that comply with international pharmaceutical standards. We source genuine Velasof Tablets from trusted manufacturers, ensuring superior product quality, secure packaging, competitive pricing, and dependable worldwide delivery. Our commitment to excellence, ethical pharmaceutical distribution, and customer satisfaction has made Ayurmed Medicose a trusted partner for hospitals, pharmacies, healthcare professionals, wholesalers, and international buyers. By delivering reliable Hepatitis C treatment solutions with uncompromising quality, we continue to support improved patient care and better healthcare outcomes across global markets.